StockData
Journey Medical Corp logo

Journey Medical Corp (DERM) shareholders

DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value
$4.33−0.06 (-1.37%)

Close on Nov 13, 2026Market cap $122.21MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
37.8%
11M of 28M shares
Institutional holders
71
23 new, 23 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Wasatch Advisors LP2,449,25311.00%13G (passive) amendmentSep 30, 2026
Tang Capital Management, LLC
Joint filing with Kevin Tang (8.00%)
1,854,5968.00%13G (passive) amendmentMar 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of DERMValueChange% of portfolio
Wasatch Advisors LP2,858,93010.13%$20.24M+725,5600.13%
Tang Capital Management LLC1,610,0005.70%$11.40M–0.52%
Vanguard Capital Management LLC675,1852.39%$4.78M−406,8950.00%
Punch & Associates Investment Management, Inc.536,0001.90%$3.79MNew0.19%
Pale Fire Capital SE528,5841.87%$3.74M+46,5970.26%
Opaleye Management Inc.350,0001.24%$2.48M−610,0000.22%
Summit Financial, LLC346,7481.23%$2.45M−33,0590.03%
Jane Street Group, LLC320,0211.13%$2.27MNew0.00%
Diametric Capital, LP295,6631.05%$2.09M+99,2510.22%
Ikarian Capital, LLC251,4360.89%$1.78M–0.19%
Renaissance Technologies LLC229,7000.81%$1.63M−12,8000.00%
Geode Capital Management, LLC216,0040.77%$1.53M−247,1980.00%
American Financial Group Inc180,0000.64%$1.27M–0.45%
Trexquant Investment LP171,3380.61%$1.21M+143,2420.01%
Marshall Wace, Llp139,8430.50%$990.09KNew0.00%
J. Goldman & Co LP137,5840.49%$974.10K−362,6040.03%
Millennium Management LLC110,0160.39%$778.91K−273,0510.00%
BlackRock, Inc.100,9810.36%$714.95K−871,8810.00%
XTX Topco Ltd100,9230.36%$714.54K+71,5590.01%
Vanguard Fiduciary Trust Co94,7290.34%$670.68K−42,9770.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20267111M37.8%23 / 1923 / 233M4M
Q1 20267212M42.0%13 / 3218 / 173M2M
Q4 20257711M39.1%17 / 3414 / 73M0M
Q3 2025689M30.8%17 / 2216 / 52M0M
Q2 2025566M23.0%25 / 1411 / 72M1M
Q1 2025385M18.0%6 / 177 / 51M0M
Q4 2024374M13.4%7 / 119 / 62M0M
Q3 2024362M7.6%7 / 810 / 40M0M
Q2 2024352M8.4%13 / 66 / 111M0M
Q1 2024332M6.4%9 / 127 / 121M0M
Q4 2023361M4.8%19 / 113 / 41M2M
Q3 2023212M7.6%5 / 67 / 31M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

69 funds held DERM in Q1 2026, 46% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of DERMValue% of fundAs of
Wasatch Micro Cap Fund1,295,1734.59%$9.17M1.36%Jun 30, 2026
Wasatch Micro Cap Value Fund788,1732.79%$5.58M1.44%Jun 30, 2026
Vanguard Total Stock Market Index Fund470,4261.67%$3.33M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund186,9660.66%$1.32M0.00%Jun 30, 2026
Vanguard Russell 2000 Index Fund105,5350.37%$665.93K0.00%May 31, 2026
Fidelity Extended Market Index Fund104,0170.37%$656.35K0.00%May 31, 2026
iShares Micro-Cap ETF50,9310.18%$360.59K0.02%Jun 30, 2026
Fidelity Total Market Index Fund41,3810.15%$261.11K0.00%May 31, 2026
Fidelity Series Total Market Index Fund28,6100.10%$180.53K0.00%May 31, 2026
Vanguard Russell 2000 Growth Index Fund19,1260.07%$120.69K0.01%May 31, 2026
Fidelity Nasdaq Composite Index Fund14,0640.05%$88.74K0.00%May 31, 2026
Vanguard Balanced Index Fund10,4180.04%$73.76K0.00%Jun 30, 2026
Invesco NASDAQ Future Gen 200 ETF9,4050.03%$59.35K0.31%May 31, 2026
Small Cap Index Fund8,5450.03%$53.92K0.00%May 31, 2026
Vanguard Institutional Total Stock Market Index Fund7,3750.03%$52.22K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Claude MaraouiPresident & CEO, Director2,435,9908.63%Apr 24, 2026
Ramsey AlloushChief Operating Officer598,5432.12%Apr 24, 2026
Joseph BeneschCFO261,3710.93%Apr 24, 2026
Miranda Jayne ToledanoDirector168,6180.60%Jul 2, 2026
Justin Adam SmithDirector231,6180.82%Jul 2, 2026
Neil HerskowitzDirector168,6180.60%Jul 2, 2026
Michael Cooper PearceDirector67,1730.24%Jun 26, 2026
Lindsay A. Rosenwald MdDirector397,6161.41%Jun 26, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Neil Herskowitz
Director
Jul 1, 2026Award+50,000––168,618
Justin Adam Smith
Director
Jul 1, 2026Award+50,000––231,618
Miranda Jayne Toledano
Director
Jul 1, 2026Award+50,000––168,618
Miranda Jayne Toledano
Director
Jun 25, 2026Award+10,000––118,618
Lindsay A. Rosenwald Md
Director
Jun 25, 2026Award+10,000––221,146
Michael Cooper Pearce
Director
Jun 25, 2026Award+10,000––67,173
Neil Herskowitz
Director
Jun 25, 2026Award+10,000––118,618
Justin Adam Smith
Director
Jun 25, 2026Award+10,000––181,618
Joseph Benesch
CFO
Apr 22, 2026Award+28,907––261,371
Ramsey Alloush
Chief Operating Officer
Apr 22, 2026Award+46,863––598,543
Claude Maraoui
President & CEO, Director
Apr 22, 2026Award+49,277––2,435,990
Claude Maraoui
President & CEO, Director
Aug 25, 2025Tax withholding−10,877$7.47$81.25K2,386,713
Claude Maraoui
President & CEO, Director
Aug 25, 2025Option exercise+1,250,000$0.07$87.50K2,397,590
Neil Herskowitz
Director
Aug 5, 2025Award+20,000––108,618
Miranda Jayne Toledano
Director
Aug 5, 2025Award+20,000––108,618
Lindsay A. Rosenwald Md
Director
Aug 5, 2025Award+50,000––211,146
Michael Cooper Pearce
Director
Aug 5, 2025Award+20,000––57,173
Justin Adam Smith
Director
Aug 5, 2025Award+20,000––171,618
Michael Cooper Pearce
Director
Jun 25, 2025Award+7,173––37,173
Lindsay A. Rosenwald Md
Director
Jun 25, 2025Award+7,173––161,146
Neil Herskowitz
Director
Jun 25, 2025Award+7,173––88,618
Justin Adam Smith
Director
Jun 25, 2025Award+7,173––151,618
Miranda Jayne Toledano
Director
Jun 25, 2025Award+7,173––88,618
Joseph Benesch
CFO
Jun 17, 2025Award+28,907––232,464
Claude Maraoui
President & CEO, Director
Jun 17, 2025Award+49,277––2,397,590
Ramsey Alloush
Chief Operating Officer
Jun 17, 2025Award+46,863––551,680
Joseph Benesch
CFO
May 2, 2025Sale−2,409$6.84$16.48K203,557
Ramsey Alloush
COO
May 2, 2025Sale−2,857$6.84$19.54K504,817
Claude Maraoui
President & CEO, Director
May 2, 2025Sale−4,834$6.84$33.06K2,348,313
Claude Maraoui
President & CEO, Director
Mar 11, 2025Sale−49,271$5.01$246.85K2,003,147
Claude Maraoui
President & CEO, Director
Mar 7, 2025Sale−14,905$5.01$74.67K2,052,418
Claude Maraoui
President & CEO, Director
Mar 6, 2025Sale−25,551$5.04$128.78K2,067,323
Claude Maraoui
President & CEO, Director
Mar 5, 2025Sale−18,147$5.13$93.09K2,092,874
Claude Maraoui
President & CEO, Director
Mar 4, 2025Sale−28,901$5.04$145.66K2,111,021
Claude Maraoui
President & CEO, Director
Mar 3, 2025Sale−23,508$5.19$122.01K2,139,922
Joseph Benesch
CFO
Feb 21, 2025Sale−1,365$5.19$7.08K45,966
Joseph Benesch
CFO
Aug 1, 2024Sale−9,324$5.47$51.00K47,331
Joseph Benesch
CFO
Jul 23, 2024Sale−4,055$5.40$21.90K56,655
Michael Cooper Pearce
Director
Jul 19, 2024Award+30,000––30,000
Miranda Jayne Toledano
Director
Jul 8, 2024Award+9,728––81,445
Neil Herskowitz
Director
Jul 8, 2024Award+9,728––81,445
Justin Adam Smith
Director
Jul 8, 2024Award+9,728––144,445
Lindsay A. Rosenwald Md
Director
Jul 8, 2024Award+9,728––153,973
Joseph Benesch
CFO
May 1, 2024Award+80,000––205,966
Claude Maraoui
President & CEO, Director
May 1, 2024Award+175,000––2,353,147
Lindsay A. Rosenwald Md
Director
Mar 25, 2024Buy+10,000$3.04$30.40K144,245
Lindsay A. Rosenwald Md
Director
Mar 22, 2024Buy+20,000$3.40$68.00K134,245
Justin Adam Smith
Director
Mar 22, 2024Buy+30,000$3.47$104.10K134,717
Claude Maraoui
President & CEO, Director
Mar 22, 2024Buy+10,000$3.48$34.80K2,163,430
Joseph Benesch
Interim CFO
Feb 22, 2024Sale−2,450$3.75$9.19K60,710
Joseph Benesch
CFO
Jan 3, 2024Award+80,000––125,966
Claude Maraoui
President & CEO, Director
Jan 3, 2024Award+175,000––2,178,147
Jeffrey Paley
Director
Nov 28, 2023Sale−1,745$5.22$9.11K70,727
Jeffrey Paley
Director
Nov 8, 2023Sale−255$3.76$959114,217
Jeffrey Paley
Director
Nov 7, 2023Sale−2,245$3.48$7.81K114,472
Justin Adam Smith
Director
Oct 13, 2023Buy+33,000$2.98$98.34K104,717
Jeffrey Paley
Director
Oct 6, 2023Buy+15,000$2.98$44.70K72,472
Jeffrey Paley
Director
Sep 21, 2023Buy+30,000$2.97$89.10K57,472
Lindsay A. Rosenwald Md
Director
Sep 6, 2023Buy+100,000$2.23$223.00K114,245
Claude Maraoui
President & CEO, Director
Sep 6, 2023Buy+26,044$2.52$65.63K2,153,430

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
12.91%
3M shares short
Days to cover
15.1
At 0M shares a day
Change since last report
+3.2%
From 3M shares
Short volume, 20 days
44.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Journey Medical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 16,031 shares on Sep 25, 2026 over the last 90 days.

See a number that looks wrong?